Key Highlights

  • NewGenIvf Group (NASDAQ:NIVF) was quoted at USD 0.5121, a 26.05% decline, during trading on November 5, 2026, per published market data.
  • A 1-for-8 reverse split of its Class A ordinary shares became effective October 23, 2026, as shown in a Nasdaq corporate actions alert that assigned a new CUSIP of G0544E162.
  • An earlier 1-for-3 reverse split was scheduled for January 26, 2026, and published coverage tallies four reverse splits during 2026 so far.
  • Published coverage reports a USD 1.25 million offering at USD 0.07 per share announced September 29, 2026, a figure treated as single-source.

The Reverse Split Behind the Price

NewGenIvf Group Limited (NASDAQ:NIVF) finished a 1-for-8 reverse split of its Class A ordinary shares effective Friday, October 23, 2026, per a Nasdaq corporate actions alert that also gave it a new CUSIP, G0544E162. A reverse split reduces the share count and multiplies the quoted price by the same factor, leaving the company's Market Value untouched. Companies often use it to get back above the USD 1 minimum bid Nasdaq requires. Before this, the company announced a 1-for-3 reverse split effective January 26, 2026, and published coverage counts four splits in 2026. During trading on November 5, 2026, the published market data had the shares at USD 0.5121, down 26.05%, on Volume of about 86,140 shares. Published coverage placed the November 4 close near USD 0.69, so the move fits a continued slide from that level.

Dilution and Financing Pattern

Published coverage describes heavy dilution ahead of the latest split. It says the company announced on September 29, 2026 an offering of roughly 17.86 million shares or pre-funded warrants at USD 0.07 each, targeting expected gross proceeds of about USD 1.25 million, with Aegis Capital acting as Placement agent. The proceeds were said to fund the K25.ai investment, Debt restructuring, Nodexus machine Manufacturing and general working capital. That detail comes from published coverage rather than a filing reviewed here, so it remains unconfirmed. The same coverage mentions a convertible note exchange in August. When a company keeps selling shares at lower prices, each issuance adds supply, pressures the price further and can prompt another reverse split, a loop that tends to wear down value for existing holders. According to published coverage, NewGenIvf operates in fertility services.

Risks and What to Watch

NewGenIvf is a micro-cap, so a few trades can move the price. Spreads can be wide, quoted moves can reverse, and nothing about the 26.05% drop implies a continued decline or a recovery. Published market data show a market value near USD 633,000, while other pages show different figures, so the company's size is itself uncertain. The same data carry an Earnings Per Share figure above 10,000 and a price-to-earnings ratio of 0.00, values that cannot apply to this business, so they are discarded. Repeated reverse splits and a sub-dollar price raise the odds of listing compliance problems, although no specific Nasdaq deadline was verified here. Investors should watch filings on new offerings, any Nasdaq notices, the next half-year results and whether the share price holds above USD 1 after the split.

Where Things Stand

NewGenIvf Group (NASDAQ:NIVF) most plausibly fell 26.05% because a reverse split does not address the underlying dilution cycle, and the price kept sliding from about USD 0.69 to USD 0.5121. A 1-for-8 split lifts the quote mechanically but leaves value unchanged, and the financing pattern in published coverage points to further share issuance. The balance of evidence is negative to cautious for holders, with little verified fundamental news to offset it. The next catalysts are new offering filings, Nasdaq listing correspondence and any reported results.